R&G PharmaStudies Co. Ltd. A - Asset Resilience Ratio
R&G PharmaStudies Co. Ltd. A (301333) has an Asset Resilience Ratio of 35.96% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read R&G PharmaStudies Co. Ltd. A total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2023–2024)
This chart shows how R&G PharmaStudies Co. Ltd. A's Asset Resilience Ratio has changed over time. See net assets of R&G PharmaStudies Co. Ltd. A for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down R&G PharmaStudies Co. Ltd. A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see R&G PharmaStudies Co. Ltd. A market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥830.86 Million | 35.96% |
| Total Liquid Assets | CN¥830.86 Million | 35.96% |
Asset Resilience Insights
- Very High Liquidity: R&G PharmaStudies Co. Ltd. A maintains exceptional liquid asset reserves at 35.96% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
R&G PharmaStudies Co. Ltd. A Industry Peers by Asset Resilience Ratio
Compare R&G PharmaStudies Co. Ltd. A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for R&G PharmaStudies Co. Ltd. A (2023–2024)
The table below shows the annual Asset Resilience Ratio data for R&G PharmaStudies Co. Ltd. A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 30.29% | CN¥707.61 Million ≈ $103.55 Million |
CN¥2.34 Billion ≈ $341.86 Million |
-4.06pp |
| 2023-12-31 | 34.35% | CN¥712.39 Million ≈ $104.24 Million |
CN¥2.07 Billion ≈ $303.46 Million |
-- |
About R&G PharmaStudies Co. Ltd. A
R&G PharmaStudies Co., Ltd. operates as a clinical trial outsourcing service provider in China and internationally. It provides drug clinical research and development integrated services. The company's services include clinical trial operation, clinical trial site management, biological sample testing, data management and statistical analysis, clinical trial consulting, and clinical pharmacology … Read more